About

About Morphocell Technologies Inc. Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its stem cell-derived engineered tissues for organ replacement therapy. Through an allogeneic approach, strong preclinical data in small and large animals and key hurdles in manufacturing already de-risked, Morphocell is rapidly approaching the clinical phases. ReLiver®, our lead product, is an implantable, fully mature, engineered liver tissue that allows for the allogeneic treatment of acute and acute-on-chronic liver failure (a $14B market), without the need of immunosuppression. Supported by a $40M series A round and strong partnerships, ReLiver is now less than 30 months away from a first-in-human clinical trial. With 24 FTE, a solid IP position and new state-of-the-art HQ and laboratories, Morphocell established its leadership in the liver cell therapy space. About Morphocell Technologies Inc. Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its stem cell-derived engineered tissues for organ replacement therapy. Through an allogeneic approach, strong preclinical data in small and large animals and key hurdles in manufacturing already de-risked, Morphocell is rapidly approaching the clinical phases. ReLiver®, our lead product, is an implantable, fully mature, engineered liver tissue that allows for the allogeneic treatment of acute and acute-on-chronic liver failure (a $14B market), without the need of immunosuppression. Supported by a $40M series A round and strong partnerships, ReLiver is now less than 30 months away from a first-in-human clinical trial. With 24 FTE, a solid IP position and new state-of-the-art HQ and laboratories, Morphocell established its leadership in the liver cell therapy space. Morphocell Technologies is a Montreal-based, preclinical regenerative medicine company focused on the development and commercialization of cell therapies and engineered tissues aimed at treating severe organ deficiencies. Morphocell is developing an extensive platform based on its allogeneic stem cell-derived engineered tissues for organ replacement therapy. Morphocell’s first therapeutic development product, ReLiver®, allows for the allogeneic treatment of acute and acute-on-chronic liver failure. Transient implantation of ReLiver® results in improved survival, treats hepatic encephalopathy and accelerates the recipient’s liver regeneration, all without the need of immunosuppression. Morphocell Technologies is a preclinical-stage regenerative medicine company founded in 2018, specializing in stem cell-derived therapies for severe liver diseases. Our flagship product, ReLiver®, is an encapsulated liver tissue designed to restore function and promote organ regeneration without the need for immunosuppression.